 ROCKVILLE, Md., Sept. 02, 2021 GLOBE NEWSWIRE -- Supernus Pharmaceuticals, Inc. Nasdaq: SUPN, a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system CNS diseases, today announced that the U.S. Food and Drug Administration FDA has acknowledged it has received the supplemental new drug application sNDA for Qelbree viloxazine extended-release capsules for the treatment of attention-deficit hyperactivity disorder ADHD in adult patients. The sNDA is now considered filed, with a user fee goal date PDUFA date of April 29, 2022. 